Loading...
•
Sep 30, 2023
Humacyte Q3 2023 Earnings Report
Announced third quarter results, highlighting positive top line results from the V005 Phase 2/3 trial and progress towards planned BLA filing.
Key Takeaways
Humacyte announced positive top line results from its V005 Phase 2/3 trial of the HAV in vascular trauma repair and plans to file a BLA for an indication in vascular trauma with the FDA during the current quarter. The company reported cash and cash equivalents of $100.0 million as of September 30, 2023.
Positive top line results from the V005 Phase 2/3 trial of the Human Acellular Vessel™ (HAV™) in vascular trauma repair.
BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter.
The HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks.
Cash and cash equivalents of $100.0 million as of September 30, 2023.
Forward Guidance
Humacyte believes that its cash and cash equivalents and expected funding from the Oberland arrangement are adequate to finance operations past the currently anticipated timelines for FDA approval and commercialization of the HAV in the vascular trauma indication.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...